AGF Management Ltd. Has $428.48 Million Holdings in Boston Scientific Co. (NYSE:BSX)

AGF Management Ltd. trimmed its position in Boston Scientific Co. (NYSE:BSX - Free Report) by 2.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,797,121 shares of the medical equipment provider's stock after selling 120,000 shares during the quarter. Boston Scientific comprises about 2.2% of AGF Management Ltd.'s investment portfolio, making the stock its 6th biggest position. AGF Management Ltd. owned about 0.33% of Boston Scientific worth $428,479,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. State Street Corp lifted its holdings in shares of Boston Scientific by 2.3% in the 3rd quarter. State Street Corp now owns 62,846,328 shares of the medical equipment provider's stock worth $5,266,522,000 after buying an additional 1,389,172 shares during the period. Wellington Management Group LLP raised its position in Boston Scientific by 2.2% during the 3rd quarter. Wellington Management Group LLP now owns 32,820,828 shares of the medical equipment provider's stock worth $2,750,385,000 after buying an additional 718,515 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Boston Scientific by 1.7% in the 3rd quarter. Geode Capital Management LLC now owns 29,584,841 shares of the medical equipment provider's stock valued at $2,469,607,000 after buying an additional 480,729 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Boston Scientific by 5.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 8,475,031 shares of the medical equipment provider's stock valued at $756,990,000 after buying an additional 456,654 shares in the last quarter. Finally, Fisher Asset Management LLC boosted its stake in Boston Scientific by 21.6% during the 4th quarter. Fisher Asset Management LLC now owns 5,800,912 shares of the medical equipment provider's stock worth $518,138,000 after purchasing an additional 1,028,977 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Jeffrey B. Mirviss sold 4,675 shares of the business's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $104.25, for a total transaction of $487,368.75. Following the sale, the executive vice president now directly owns 28,454 shares of the company's stock, valued at $2,966,329.50. The trade was a 14.11 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP John Bradley Sorenson sold 4,119 shares of Boston Scientific stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total value of $370,792.38. Following the completion of the transaction, the executive vice president now directly owns 35,319 shares of the company's stock, valued at approximately $3,179,416.38. This trade represents a 10.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 137,302 shares of company stock valued at $14,319,269 in the last ninety days. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Price Performance

Shares of Boston Scientific stock opened at $93.79 on Tuesday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The firm's 50-day simple moving average is $100.54 and its 200-day simple moving average is $91.37. The firm has a market cap of $138.42 billion, a P/E ratio of 75.04, a price-to-earnings-growth ratio of 2.79 and a beta of 0.77. Boston Scientific Co. has a twelve month low of $65.52 and a twelve month high of $107.17.

Remove Ads

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. As a group, research analysts expect that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. StockNews.com lowered Boston Scientific from a "buy" rating to a "hold" rating in a research report on Saturday. Canaccord Genuity Group upped their price target on Boston Scientific from $98.00 to $101.00 and gave the stock a "buy" rating in a report on Monday, December 9th. Piper Sandler lifted their price target on shares of Boston Scientific from $95.00 to $115.00 and gave the company an "overweight" rating in a report on Monday, February 3rd. Stifel Nicolaus raised their target price on Boston Scientific from $100.00 to $115.00 and gave the company a "buy" rating in a research note on Thursday, February 6th. Finally, Argus set a $130.00 price objective on Boston Scientific in a report on Tuesday, February 18th. Two research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $108.91.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.